Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma

被引：12

作者：

Zain, Jasmine ^{[1
]}

机构：

[1] NYU Langone Med Ctr, Div Hematol Malignancies & Med Oncol, New York, NY 10016 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2012年 / 26卷 / 03期

关键词：

Histone deacetylase inhibitors; Lymphoma; Multiple myeloma; Epigenetic therapy; SUBEROYLANILIDE HYDROXAMIC ACID; PERIPHERAL T-CELL; PHASE-II TRIAL; VALPROIC ACID; GENE-EXPRESSION; DEPSIPEPTIDE FR901228; HODGKIN LYMPHOMA; HDAC INHIBITOR; EPIGENETIC THERAPIES; FK228; DEPSIPEPTIDE;

D O I：

10.1016/j.hoc.2012.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histone deacetylase inhibitors (HDACI) have allowed pharmacologic manipulation of deregulated genes in cancer cells and have shown single-agent activity against T cell lymphomas, cutaneous T cell lymphomas, mantle cell lymphomas, and Hodgkin disease. The bigger promise of these agents is in enhancing the activity of other targeted therapies. In addition, the effects of HDACI on the immune system and cytokines indicate that HDACI can be useful in the treatment of immune dysfunction underlying tumorigenesis, autoimmune disorders, and graft-versus-host disease. There is also an effort to determine whether class specificity of HDACI has a biologic significance.

引用

页码：671 / +

页数：35

共 180 条

[51] Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO [J].

Gelmetti, V ;

Zhang, JS ;

Fanelli, M ;

Minucci, S ;

Pelicci, PG ;

Lazar, MA .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) :7185-7191

[52] A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia [J].

Gimsing, Peter ;

Hansen, Mads ;

Knudsen, Lene M. ;

Knoblauch, P. ;

Christensen, Ib Jarle ;

Ooi, Chean Eng ;

Buhl-Jensen, Peter .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (03) :170-176

[53] Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors [J].

Gloghini, Annunziata ;

Buglio, Daniela ;

Khaskhely, Noor M. ;

Georgakis, Georgios ;

Orlowski, Robert Z. ;

Neelapu, Sattva S. ;

Carbone, Antonino ;

Younes, Anas .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) :515-525

[54] The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells [J].

Golay, J. ;

Cuppini, L. ;

Leoni, F. ;

Mico, C. ;

Barbui, V. ;

Domenghini, M. ;

Lombardi, L. ;

Neri, A. ;

Barbui, A. M. ;

Salvi, A. ;

Pozzi, P. ;

Porro, G. ;

Pagani, P. ;

Fossati, G. ;

Mascagni, P. ;

Introna, M. ;

Rambaldi, A. .

LEUKEMIA, 2007, 21 (09) :1892-1900

[55] Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL [J].

Gomez-Benito, Maria ;

Martinez-Lorenzo, Maria Jose ;

Anela, Alberto ;

Marzo, Isabel ;

Naval, Javier .

EXPERIMENTAL CELL RESEARCH, 2007, 313 (11) :2378-2388

[56]

Gray SG, 2004, INT J ONCOL, V24, P773

[57] Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis [J].

Gregoretti, IV ;

Lee, YM ;

Goodson, HV .

JOURNAL OF MOLECULAR BIOLOGY, 2004, 338 (01) :17-31

[58] Histone acetylation in chromatin structure and transcription [J].

Grunstein, M .

NATURE, 1997, 389 (6649) :349-352

[59] Cotreatment with histone deacetylase inhibitor LAQ824 enhances apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells [J].

Guo, F ;

Sigua, C ;

Tao, JG ;

Bali, P ;

George, P ;

Li, YQ ;

Wittmann, S ;

Moscinski, L ;

Atadja, P ;

Bhalla, K .

CANCER RESEARCH, 2004, 64 (07) :2580-2589

[60]

Hagelkruys Astrid, 2011, Handb Exp Pharmacol, V206, P13, DOI 10.1007/978-3-642-21631-2_2

← 1 2 3 4 5 6 7 8 9 10 →